Uric acid levels and vascular disease.
There is evidence showing that serum uric acid (SUA) levels predict the risk for vascular events. For example, up to 29% of the reduction in the primary composite endpoint seen in the LIFE trial (favouring losartan versus atenolol) can be attributed to a fall in SUA levels. We also discuss the findings of the GREACE study (treating to target with atorvastatin versus 'usual' care) in relation to SUA levels. In this brief comment we extend this argument to consider the SUA-lowering effect of other drugs commonly prescribed in patients with vascular disease (e.g. statins, fibrates and antihypertensive agents). A judicious use of drugs (alone or in combination) will result in small reductions in SUA levels. These changes may translate into a substantial reduction in the risk of vascular events. Results retrieved from completed trials together with new prospective findings will support or refute the proposed association between lowering SUA levels and reducing vascular morbidity and mortality.
Daskalopoulou
S S
SS
Department of Clinical Biochemistry (Vascular Disease Prevention Clinics), Royal Free Hospital, Royal Free and University College Medical School, London, UK.
Athyros
V G
VG
Elisaf
M
M
Mikhailidis
D P
DP
D004232:Diuretics / Q000008:administration & dosage / Q000627:therapeutic use; D006115:Greece; D006801:Humans; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D012307:Risk Factors; D014527:Uric Acid / Q000097:blood*; D014652:Vascular Diseases / Q000097:blood / Q000209:etiology*
D004232:Diuretics; D000960:Hypolipidemic Agents; D014527:Uric Acid